lobbying_activities: 921153
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 921153 | 89cab30a-ed80-4aee-adfb-89eba32c6687 | Q1 | THE DUBERSTEIN GROUP INC. | 12675 | AMERICA'S HEALTH INSURANCE PLANS | 2010 | first_quarter | PHA | Generic biologics, generic prescription drugs - HR 3962, America's Affordable Health Choices Act. Generic biologics - HR 3590, Patient Protection and Affordable Care Act. Healthcare reform, including pharmaceutical issues - HR 4872, Health Care and Education Reconciliation Act of 2010. *Antitrust exemption for pharmacies - HR 1204, To ensure and foster continued patient safety and quality of care by making the antitrust laws apply to negotiations between groups of independent pharmacies and health plans and health insurance issuers (including health plans under parts C and D of the Medicare Program) in the same manner as such laws apply to protected activities under the National Labor Relations Act *Generic biologics - HR 1427, To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes; HR 1548, To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes; S 726, A bill to amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes; HR 3200, To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes; S 1679, An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. *Generic drugs - HR 1706, To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes; S 369, A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. *Prescription drug co-pays and formularies - S 1630, A bill to amend title XVIII of the Social Security Act of improve prescription drug coverage under Medicare part D and to amend the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to improve prescription drug coverage under private health insurance, and for other purposes. *Federal Employee Health Benefit Program prescription drugs - HR 4489, To amend chapter 89 of title 5, United States Code, to ensure program integrity, transparency, and cost savings in the pricing and contracting of prescription drug benefits under the Federal Employees Health Benefits Program. | HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 100000 | 0 | 0 | 2010-04-19T12:26:37.040000-04:00 |